FAM83B

Across TCGA pan-cancer cohorts, FAM83B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM83B data layer compared with 21 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher FAM83B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM83B expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, LUAD, and HNSC are the cancer types where FAM83B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	1.000	0.860	.001	35	view →
LUAD	DFS	Median	All	0.385	0.955	.002	9	view →
HNSC	DFS	Quartile	II,III,IV	0.981	0.842	.009	9	view →
PDAC	DFS	Tertile	III,IV	0.900	0.454	.036	3	view →
UCEC	DFS	Median	All	1.000	0.938	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM83B–LSCC (DFS)

Open the LSCC breakdown →